UroGen Pharma (URGN) Insider Stuart Holden Buys 20,000 Shares

Stuart Holden made a significant move by purchasing 20,000 shares of URGN on June 22, 2026. The transaction was not part of a pre-planned trading scheme, but the price at which the shares were acquired wasn't disclosed.

Other Institutional Activity in URGN

RTW Investments, LP maintained its position in URGN with 4,543,895 shares valued at about $81.7 million. BlackRock, Inc. increased its stake by 244,558 shares, ending with 2,845,567 shares worth roughly $51.2 million, marking a 9.4% increase. Toronto Dominion Bank and Kynam Capital Management, LP both opened new positions, holding 2,616,714 and 2,247,393 shares valued at approximately $47.0 million and $40.4 million, respectively. Morgan Stanley slightly trimmed its holdings by 2,863 shares to 2,560,038 shares, valued at around $46.0 million.

UroGen Pharma Ltd. Stock Down 17.2%

Shares of URGN traded near $35.80 on Wednesday. The stock has been a focus for investors, with several institutional activities reflecting varied interests in the company.

Insider Buying and Selling at UroGen Pharma Ltd.

On June 22, 2026, several insiders at URGN made notable purchases. Robinson James Jr. bought 8,000 and 10,000 shares in two separate transactions. Leana Wen acquired 10,000 shares, while Arie Belldegrun purchased 20,000 shares. Additionally, Cynthia Butitta and Daniel George Wildman each bought 10,000 shares. None of these transactions were part of a pre-planned trading plan.

Analysts Set New Price Targets

On May 11, 2026, HC Wainwright & Co. maintained its 'buy' rating for URGN, setting a price target of $45. Oppenheimer also maintained a 'buy' rating on May 7, 2026, with a target of $40. The consensus among analysts remains positive, with a strong buy recommendation.

About URGN

URGN is a biopharmaceutical company focused on developing and commercializing novel therapies to treat urothelial and specialty cancers. The company aims to address unmet medical needs, offering innovative solutions for patients worldwide.

Bottom Line

Stuart Holden's recent purchase of 20,000 shares of URGN signals confidence in the company's future. The stock's trading activity and insider transactions suggest a keen interest among investors. As always, remember that insider activity and analyst ratings are just part of the broader picture in evaluating a company's potential.